On CNBC’s “Mad Money Lightning Round,” Jim Cramer said Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a “very controversial” stock.

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterated a Sell rating on Sarepta Therapeutics on Monday and maintained a $5 price target.

Avery Dennison Corporation (NYSE:AVY) is a “winner,” Cramer said. “It always sells for a reasonable multiple.”

On the earnings front, Avery Dennison said it will host its third-quarter earnings conference call on Thursday, Oct. 29. Analysts expect the company to report quarterly earnings at $2.33 per share on revenue of $2.26 billion.

When asked about FirstCash Holdings, Inc. (NASDAQ:FCFS), he said, “Because it’s a pawn shop company, I don’t understand that business model well enough to be able to opine on it.”

Stephens & Co. analyst Kyle Joseph reiterated FirstCash with an Overweight rating on Oct. 1 and maintained a $250 price target.

Ciena Corporation (NYSE:CIEN) is “very good,” Cramer said. “I happen to like optical. You know, the one that I had liked for the Club was Corning. I’m waiting for it to come down and be able to get back in.”

Supporting his choice, Bernstein analyst Daniel Zhu, on Sept. 30, initiated coverage on Ciena with an Outperform rating and set a price target of $440.

“People are very worried about Europe right now because of France. I think ING is good,” Cramer said when asked about ING Groep N.V. (NYSE:ING). “I happen to like Banco Santander (NYSE:SAN) very much too. I think you’re in good shape.”

ING Group reported better-than-expected second-quarter financial results on July 30.

Price Action

  • Avery Dennison shares gained 0.1% to settle at $170.00 on Monday.
  • Ciena shares slipped 0.4% to close at $389.69 during the session.
  • FirstCash rose 0.5% to settle at $211.33 on Monday.
  • ING Groep shares slipped 0.03% to close at $34.77.
  • Sarepta Therapeutics shares fell 0.1% to settle at $17.49 on Monday.

See More: Top Value Stocks

Photo via Shutterstock